Candida auris is an emerging multidrug-resistant fungal pathogen that has gained attention due to its ability to cause severe infections and its capacity to persist in healthcare environments (Du et al., 2020). Its pathogenicity is attributed to several factors, including environmental contamination, rapid spreading, intrinsic and acquired resistance to antifungal drugs and disinfectants, its ability to adhere to and invade host tissues, and its ability to form biofilms (Caceres et al., 2019; Du et al., 2020; Horton and Nett, 2020; Ahmad and Alfouzan, 2021; Sharma and Goel, 2022).

C. auris has been found to persist in the environment, particularly in healthcare settings. Studies have shown that the fungus can survive on various surfaces, such as bed rails, furniture, and medical equipment, leading to environmental contamination and increasing the risk of transmission (Ahmad and Alfouzan, 2021). Also, it has been associated with outbreaks in healthcare facilities and has the potential to spread rapidly within these settings. Person-to-person transmission has been observed, and the fungus can also spread to the general population through healthcare workers or contaminated equipment (Jeffery-Smith et al., 2018; Du et al., 2020; Ahmad and Asadzadeh, 2023). It has been found to have intrinsic resistance to multiple classes of antifungal drugs, including azoles, echinocandins, and polyenes. This intrinsic resistance is thought to be due to genetic changes in the target enzymes or membrane components that are involved in drug susceptibility (Chowdhary et al., 2020). One of the key factors that contributes to the pathogenicity of C. auris is its ability to adhere to host tissues and form biofilms. Biofilms are complex communities of microorganisms encased in a self-produced extracellular matrix, which protects the organisms from host immune responses and antimicrobial treatments. C. auris has been shown to form robust biofilms on various surfaces, including medical devices and human tissues, allowing it to establish persistent infections (Jeffery-Smith et al., 2018; Caceres et al., 2019).

Furthermore, C. auris has been associated with high mortality rates in infected individuals, particularly those with underlying health conditions or compromised immune systems. The ability of C. auris to cause invasive infections, such as bloodstream infections, has been linked to its ability to disseminate within the host and evade host immune responses (Du et al., 2020; Ahmad and Alfouzan, 2021).

It is important to note that the exact mechanisms of C. auris pathogenicity are still being investigated, and there is ongoing research to better understand its virulence factors and the host immune responses to this pathogen.

Aspergillus fumigatus is a ubiquitous environmental fungus which is considered the most clinically significant species within the genus Aspergillus. It primarily affects the respiratory system and can spread to other organs, leading to high mortality rates. Its pathogenicity is attributed to several factors, including its ability to produce a variety of virulence factors and its ability to adapt and survive in different environments (Jafarlou et al., 2008; van de Veerdonk et al., 2017).

One of the key virulence factors of A. fumigatus is its production of secondary metabolites, such as gliotoxin. Gliotoxin is a potent immunosuppressive and cytotoxic compound that can inhibit the function of immune cells, such as neutrophils, macrophages, and dendritic cells, thereby allowing the fungus to evade the host immune response (Knowles et al., 2020).

Another important virulence factor is the ability of A. fumigatus to form biofilms. Biofilms are complex microbial communities that adhere to surfaces and are encased in a self-produced extracellular matrix. A. fumigatus biofilms have been shown to enhance the resistance of the fungus to antifungal drugs and to host immune defenses, allowing for persistent infection (Liu et al., 2022).

In addition, A. fumigatus produces enzymes, such as proteases and elastases, which can degrade host tissues and contribute to tissue invasion and damage (Ghazaei, 2017).

The ability of A. fumigatus to grow at physiological temperature (37°C) is also a critical factor in its pathogenicity. Unlike many other Aspergillus species that primarily cause infections in plants and animals, A. fumigatus has adapted to survive and grow at human body temperature, allowing it to colonize and infect human hosts (Mousavi et al., 2016).

Furthermore, the presence of asexual spores called conidia is another important aspect of A. fumigatus pathogenicity. The small size and hydrophobic nature of the conidia allow them to be easily inhaled and reach the lower respiratory tract. Once in the lungs, conidia can germinate and establish infection (Blatzer and Latgé, 2021).

It is worth noting that the pathogenesis of A. fumigatus infections is complex and involves interactions between the fungus and the host immune system and has shown increasing resistance to antifungal drugs, making treatment options limited. Climate change and environmental factors may contribute to the expansion of A. fumigatus habitats, increasing the risk of human exposure and potential for a pandemic (Verweij et al., 2016; van de Veerdonk et al., 2017).

Cryptococcus neoformans is a globally distributed fungal pathogen that primarily affects individuals with weakened immune systems, such as those with HIV/AIDS or undergoing immunosuppressive therapy (Rathore et al., 2022; Zhao et al., 2023). Its pathogenicity is attributed to several factors, including its ability to evade immune responses, its production of virulence factors, and its capacity to form a protective polysaccharide capsule. One of the key factors contributing to the pathogenicity of C. neoformans is its ability to evade immune responses. The polysaccharide capsule surrounding the fungus plays a crucial role in evading phagocytosis by host immune cells. The capsule inhibits recognition by host immune cells and interferes with the activation of immune response pathways, allowing the pathogen to survive and proliferate within the host (Alanio et al., 2015; Zaragoza, 2019; Rathore et al., 2022).

C. neoformans also produces various virulence factors that contribute to its pathogenicity. One such factor is melanin, which is produced by the fungus and provides protection against oxidative stress and phagocytosis. Melanin also inhibits the production of pro-inflammatory cytokines, further aiding the fungus in evading immune responses (Guerrero et al., 2006).

Furthermore, C. neoformans can undergo a process called phenotypic switching, where it can switch between different phenotypes, such as smooth and rough colonies. The smooth phenotype, associated with a thicker capsule, is more virulent and resistant to phagocytosis compared to the rough phenotype (Fries et al., 2002; Guerrero et al., 2006; Jain and Fries, 2008).

Another important aspect of C. neoformans pathogenicity is its ability to cause meningoencephalitis, a severe infection of the brain and meninges. The fungus can cross the blood–brain barrier and invade the central nervous system, leading to inflammation and neurological symptoms. The production of certain enzymes and factors, such as phospholipase and urease, by C. neoformans may contribute to its ability to invade and cause damage in the central nervous system (Bloom et al., 2019; Chen et al., 2022).

The emergence of multidrug-resistant strains and the potential for human-to-human transmission highlight the need for vigilance in monitoring and controlling this pathogen (Zhao et al., 2023).

Histoplasma capsulatum is a dimorphic fungus found in soil contaminated with bird or bat droppings. It causes histoplasmosis, a respiratory infection that can progress to disseminated disease in immunocompromised individuals. Its pathogenicity is attributed to its ability to survive within host macrophages, evade immune responses, and establish chronic infections in the host (Mittal et al., 2019; Nemade and Shinde, 2021).

One of the key factors contributing to the pathogenicity of H. capsulatum is its ability to survive and replicate within host macrophages. Upon inhalation of fungal spores, H. capsulatum is phagocytosed by alveolar macrophages. However, instead of being destroyed, the fungus can survive and replicate within these phagocytes. It can use several mechanisms to manipulate the host cell machinery and create an intracellular niche favorable for its growth (Deepe, 2000; Garfoot and Rappleye, 2016).

H. capsulatum also possesses the ability to evade immune responses. The fungus can modulate the host immune system by interfering with the activation of immune cells and suppressing the production of pro-inflammatory cytokines. This allows the fungus to establish a chronic infection and avoid clearance by the immune system (Mittal et al., 2019; Valdez et al., 2022).

Furthermore, H. capsulatum produces various virulence factors that contribute to its pathogenicity. One of the major virulence factors is a heat shock protein called Hsp60, which is involved in the survival and replication of the fungus within host cells. Hsp60 can also modulate host immune responses and contribute to the persistence of infection (Mihu and Nosanchuk, 2012; Mittal et al., 2019; Valdez et al., 2022).

The ability of H. capsulatum to form yeast cells is another crucial aspect of its pathogenicity. The transition from the mycelial form to the yeast form is essential for the establishment of infection. The yeast form of H. capsulatum is better adapted to survive within host tissues and evade immune recognition compared to the mycelial form (Mittal et al., 2019).

Histoplasmosis is endemic in certain regions, but its potential for dissemination through travel and migration raises concerns for a pandemic. Climate change and urbanization may also contribute to the expansion of H. capsulatum habitats, increasing the risk of exposure (Mittal et al., 2019; Linder and Kauffman, 2019).

Pneumocystis jirovecii is an opportunistic fungal pathogen that primarily affects immunocompromised individuals, particularly those with weakened immune systems such as HIV/AIDS patients. Understanding its pathogenicity is crucial for the diagnosis, treatment, and prevention of Pneumocystis pneumonia (Gingerich et al., 2021; Weyant et al., 2021).

The exact mechanisms of P. jirovecii pathogenicity are not fully understood, but several factors contribute to its ability to cause disease. One of the main factors is its unique cell wall composition, which allows it to evade host immune responses. The cell wall of P. jirovecii contains complex polysaccharides that are thought to play a role in immune evasion and modulation of host immune responses (Apostolopoulou and Fishman, 2022). P. jirovecii also possesses surface proteins that may contribute to its pathogenicity. These proteins, such as kexin-like protein and major surface glycoprotein, are involved in adhesion to host cells and host immune evasion (Ma et al., 2016; Schmid-Siegert et al., 2021). Furthermore, P. jirovecii is believed to have a high degree of genetic diversity, which may contribute to its ability to evade host immune responses and adapt to different hosts. Genetic variations in P. jirovecii strains have been associated with differences in disease severity and clinical outcomes (White et al., 2019; Bateman et al., 2020).

The pathogenicity of P. jirovecii is also influenced by the host immune status. In immunocompromised individuals, such as those with HIV/AIDS, the weakened immune system allows for uncontrolled growth and dissemination of the fungus, leading to Pneumocystis pneumonia. The specific immune responses involved in controlling P. jirovecii infection are not fully understood, but both cell-mediated and humoral immune responses are thought to play a role (Gülbudak et al., 2020; Charpentier et al., 2021). P. jirovecii is transmitted through respiratory droplets and has the potential for human-to-human transmission (Vera and Rueda, 2021). The emergence of drug-resistant strains and the increasing population of immunocompromised individuals worldwide contribute to the potential for a pandemic (Phipps et al., 2011; Vera and Rueda, 2021).

Mucormycetes, also known as zygomycetes, are filamentous fungi that can cause mucormycosis or zygomycosis in humans, particularly in individuals with compromised immune systems which are associated with high morbidity and mortality rates (Smith and Lee, 2022). Mucormycetes can enter the human body through inhalation, ingestion, or direct contact with contaminated materials. Once inside the host, these fungi have the ability to invade blood vessels, leading to tissue necrosis and the formation of characteristic fungal hyphae. The invasion of blood vessels is a key factor in their pathogenicity, as it allows for rapid spread and extensive tissue damage (Sharma and Goel, 2022).

The pathogenicity of mucormycetes is attributed to their mechanisms of iron acquisition and secretion of various enzymes and toxins. These fungi produce siderophores, which are iron-scavenging molecules that enable them to survive and proliferate in iron-limited environments, such as the human body. Additionally, they secrete enzymes, like proteases, that degrade host tissues and facilitate invasion. Furthermore, mucormycetes release mycotoxins, such as gliotoxin, which can suppress the immune response and promote fungal survival (Skiada et al., 2020; Sharma and Goel, 2022).

Early diagnosis of mucormycosis is often challenging due to nonspecific symptoms that can mimic other infections. Consequently, mucormycosis is frequently diagnosed at advanced stages when the infection has already spread. Moreover, mucormycetes are inherently resistant to many antifungal drugs, including azoles, which are commonly used for fungal infections. This limited availability of effective antifungal agents complicates treatment options for mucormycosis (Skiada et al., 2020; Sharma and Goel, 2022; Smith and Lee, 2022).

In recent times, there has been a concerning association between mucormycosis and COVID-19, leading to the term “COVID-19 associated mucormycosis” or “black fungus.” COVID-19 patients with compromised immune systems, especially those receiving corticosteroid therapy, have been reported to be at a higher risk of developing mucormycosis. The combination of COVID-19 infection and mucormycosis poses significant challenges in diagnosis and treatment, further emphasizing the need for early detection and a multidisciplinary approach to manage these cases effectively (Singh et al., 2021; Hoenigl et al., 2022).

Fungal pathogens possess adhesins, such as Candida albicans Als proteins or Aspergillus fumigatus hydrophobins, which facilitate attachment to host tissues (Naglik et al., 2003; Aimanianda and Latgé, 2010). These adhesins promote invasion and colonization of host cells. Targeting these adhesion molecules may disrupt fungal-host interactions and prevent infection.

Fungal pathogens secrete various enzymes that enable tissue invasion and nutrient acquisition. For example, Candida species produce secreted aspartyl proteinases (Saps) that degrade host proteins, impairing immune defenses (Naglik et al., 2003). Inhibiting these enzymes could potentially hinder fungal invasion and reduce tissue damage.

Certain fungal species produce toxins that contribute to their virulence. Aspergillus fumigatus releases gliotoxin, which inhibits immune cell function and promotes fungal survival (Spikes et al., 2008). Targeting toxin production pathways may offer therapeutic opportunities to weaken fungal virulence and enhance host immune responses.

Fungal pathogens, such as Candida species, can form biofilms on medical devices, leading to persistent infections. Biofilms provide protection against host immune responses and antimicrobial agents. Disrupting biofilm formation mechanisms, such as targeting key regulatory genes or inhibiting extracellular matrix production, could enhance treatment efficacy (Malinovská et al., 2023).

Fungal pathogens can acquire resistance to commonly used antifungal drugs, posing a significant challenge for treatment. The emergence of multidrug-resistant fungal pathogens is a significant concern in healthcare settings (Fisher et al., 2012). These resistant strains demonstrate resistance to multiple classes of antifungal drugs, making them difficult to treat and control. The spread of such resistant strains within healthcare facilities poses a serious threat to vulnerable patient populations (Vallabhaneni et al., 2015; Fisher et al., 2022).

One primary mechanism of antifungal resistance is the acquisition of genetic mutations or the transfer of resistance genes from other organisms. These mutations or genes can confer reduced susceptibility or complete resistance to antifungal drugs. Fungal pathogens can also employ efflux pumps to actively remove antifungal drugs from within their cells, reducing their effectiveness (Lee et al., 2023).

Fungal infections pose a significant global burden, and several factors contribute to their impact on public health. One key factor is the difficulty in diagnosing fungal infections accurately and promptly. Many fungal infections present with nonspecific symptoms that overlap with other conditions, leading to delays in diagnosis and treatment initiation. This delay can result in the progression of the infection, increased morbidity, and mortality rates (Bongomin et al., 2017).

Another crucial factor is the absence of effective vaccines for most fungal infections. Unlike bacterial or viral infections, vaccines for fungal pathogens are limited (Brown et al., 2012). Vaccines play a vital role in preventing infectious diseases by stimulating the immune system to recognize and mount a defense against specific pathogens. The lack of effective vaccines leaves individuals susceptible to fungal infections and limits preventive measures (Brown et al., 2012; Tripathi, 2023).

Transmissibility is another important factor contributing to the global burden of fungal infections. Some fungal pathogens, such as Candida auris, have demonstrated the ability to spread rapidly and cause outbreaks in healthcare settings (Vallabhaneni et al., 2015). These multidrug-resistant strains can colonize surfaces and persist in the environment, making them difficult to eradicate. This transmissibility within healthcare facilities increases the risk of fungal infections and contributes to the global burden (Vallabhaneni et al., 2015; Parmanik et al., 2022).

The limited treatment options for fungal infections also contribute to their global impact. Fungal resistance to antifungal drugs has become a significant concern (Wiederhold, 2017). Fungal pathogens can acquire genetic mutations or resistance genes, reducing their susceptibility or conferring complete resistance to antifungal agents (Lee et al., 2023). This limits the available treatment options and increases the risk of treatment failure. The emergence of multidrug-resistant fungal strains further exacerbates this problem (Lee et al., 2021, 2023).

Furthermore, immunosuppressed populations, such as individuals with HIV/AIDS, organ transplant recipients, or patients undergoing chemotherapy, are particularly vulnerable to fungal infections. Their weakened immune response makes it harder to control and eliminate fungal pathogens, leading to more severe and recurrent infections (Pappas et al., 2016).

Addressing the global burden of fungal infections requires a multidimensional approach. This includes investing in research and development for new antifungal drugs with novel mechanisms of action, improving diagnostic methods for accurate and rapid identification of fungal infections, developing effective vaccines, implementing infection prevention and control measures in healthcare settings, and raising awareness among healthcare professionals and the general public about the importance of early detection and appropriate management of fungal infections.

Indoor spaces can serve as habitats for various fungi, including pathogenic species. For example, a study conducted in the United States found that approximately 45% of homes had visible mold growth (Mendell et al., 2011). Exposure to indoor molds has been associated with respiratory symptoms, allergies, and asthma exacerbations.

Fungal infections acquired in healthcare settings, known as healthcare-associated infections (HAIs), are a significant concern. According to the Centers for Disease Control and Prevention (CDC), Candida species account for the majority of fungal HAIs in the United States (Haque et al., 2020). Candida infections can range from mild oral thrush to life-threatening bloodstream infections, with an estimated mortality rate of 40–60% for Candida bloodstream infections.

Fungal infections can also be acquired outside of healthcare settings. For instance, coccidioidomycosis, also known as Valley fever, is a fungal infection caused by the soil-dwelling fungus Coccidioides. It is endemic in certain regions of the United States, primarily in the southwestern states. In 2019, there were over 16,000 reported cases of coccidioidomycosis in the United States (Williams and Chiller, 2022).

Individuals working in certain occupations, such as agriculture or construction, may be at an increased risk of exposure to pathogenic fungi. Farmworkers, for example, can be exposed to fungi present in soil, crops, and organic matter. Occupational exposure to fungi has been associated with respiratory diseases, such as farmer’s lung and humidifier lung (Rylander, 1986).

People with weakened immune systems, such as those living with HIV/AIDS, undergoing chemotherapy, or receiving organ transplants, are particularly vulnerable to fungal infections. Invasive fungal infections, such as invasive aspergillosis or cryptococcosis, can be life-threatening in these individuals. According to the Global Action Fund for Fungal Infections (GAFFI), an estimated 1.6 million deaths occur annually due to fungal diseases worldwide, with the majority of these deaths occurring in immunocompromised individuals (Bongomin et al., 2017).

These examples and statistics demonstrate the diverse range of fungal habitats and the potential for human exposure to pathogenic fungi. It is essential to understand and address these exposures to mitigate the impact of fungal infections on human health. Public health measures, such as improving ventilation in indoor spaces, implementing infection control practices in healthcare settings, and raising awareness among high-risk populations, can help reduce the burden of fungal diseases.